automatically take effect at the end of 45 days of continuous session of Congress beginning on October 12, 2006. The 45-day review period ended on February 16, 2007. This document confirms the effective date as February 16, 2007.

DATES: *Effective Date:* The final rule published on October 12, 2006 (71 FR 60055) took effect on February 16, 2007.

FOR FURTHER INFORMATION CONTACT: Becky Shortland, Gray's Reef National Marine Sanctuary, 10 Ocean Science Circle, Savannah, Georgia 31411; 912–598–2381; *Becky.Shortland@noaa.gov*.

(Federal Domestic Assistance Catalog Number 11.429 Marine Sanctuary Program)

Dated: March 13, 2007.

John H. Dunnigan,

Assistant Administrator for Ocean Services and Coastal Zone Management.

[FR Doc. 07–1303 Filed 3–16–07; 8:45 am]

BILLING CODE 3510–08–M

SOCIAL SECURITY ADMINISTRATION

20 CFR Part 416

Revised Medical Criteria for Determination of Disability, Musculoskeletal System and Related Criteria

CFR Correction

In Title 20 of the Code of Federal Regulations, Parts 400 to 499, revised as of April 1, 2006, on page 948, § 416.933 is corrected by adding a sentence after the second sentence to read as follows:

§ 416.933 How we make a finding of presumptive disability or presumptive blindness.

* * * For other impairments, a finding of disability or blindness must be based on medical evidence or other information that, though not sufficient for a formal determination of disability or blindness, is sufficient for us to find that there is a high degree of probability that you are disabled or blind. * * *

[FR Doc. 07–55503 Filed 3–16–07; 8:45 am]

BILLING CODE 1505–01–D

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 341

[Docket No. 1976N–0052G] (formerly Docket No. 76N–052G)

Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending its regulations to change the location of a section in an over-the-counter (OTC) drug monograph. This action is editorial in nature and is intended to improve the accuracy of the agency's regulations.

DATES: This rule is effective March 19, 2007.

FOR FURTHER INFORMATION CONTACT: Gerald M. Rachanow, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 5496, Silver Spring, MD 20993, 301–796–2090.

SUPPLEMENTARY INFORMATION: FDA published the final monograph (FM) for cold, cough, allergy, bronchodilator, and antiasthmatic combination drug products for OTC human use in the **Federal Register** of December 23, 2002 (67 FR 78158). In that FM, FDA inadvertently added § 341.40 (21 CFR 341.40) to subpart C of the monograph, when that section should have been added to subpart B of the monograph. Accordingly, FDA is now moving § 341.40 from subpart C to subpart B of the monograph.

Publication of this document constitutes final action on this change under the Administrative Procedure Act (5 U.S.C. 553). Notice and public procedures are unnecessary because FDA is merely implementing a change in the location of a section in an OTC drug monograph. No other changes are being made to that section of the monograph.

List of Subjects in 21 CFR Part 341

Labeling, Over-the-counter drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 341 is amended as follows:

PART 341—COLD, COUGH, ALLERGY, BRONCHODILATOR, AND ANTIASTHMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

■ 1. The authority citation for 21 CFR part 341 continues to read as follows:

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

Subpart B—Active Ingredients [Amended]

■ 2. Remove § 341.40 *Permitted combinations of active ingredients* from subpart C and add it to subpart B of part 341.

Dated: March 12, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E7–4957 Filed 3–16–07; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF THE TREASURY

31 CFR Part 103

RIN 1506–AA83

Financial Crimes Enforcement Network; Amendment to the Bank Secrecy Act Regulations—Imposition of Special Measure Against Banco Delta Asia, Including Its Subsidiaries Delta Asia Credit Limited and Delta Asia Insurance Limited, as a Financial Institution of Primary Money Laundering Concern

AGENCY: Financial Crimes Enforcement Network, Department of the Treasury.

ACTION: Final rule.

SUMMARY: The Financial Crimes Enforcement Network (''FinCEN'') is issuing a final rule imposing a special measure against Banco Delta Asia SARL (''Banco Delta Asia'' or ''the bank'') as a financial institution of primary money laundering concern, pursuant to the authority contained in 31 U.S.C. 5318A of the Bank Secrecy Act.

DATES: This final rule is effective on April 18, 2007.

FOR FURTHER INFORMATION CONTACT: Regulatory Policy and Programs Division, Financial Crimes Enforcement Network, (800) 949–2732.

SUPPLEMENTARY INFORMATION:

I. Background

A. Statutory Provisions

On October 26, 2001, the President signed into law the Uniting and Strengthening America by Providing Appropriate Tools Required To